about
Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine developmentJapanese encephalitis: the virus and vaccinesEffective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigensCross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases.Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody ResponsesAn inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.Gamma-Irradiated Influenza A Virus Provides Adjuvant Activity to a Co-Administered Poorly Immunogenic SFV Vaccine in Mice.Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response.Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responsesProperties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.Effects of adjuvants on IgG subclasses elicited by virus-like particles.Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosisNovel methods to treat and prevent human papillomavirus infection.Genetically engineered Tobacco mosaic virus as nanoparticle vaccines.A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.The pediatrician's role in preventing cervical cancer.Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensisNanoparticle-detained toxins for safe and effective vaccination.Understanding HPV disease and prevention: a guide for school nurses.Virus-like particle vaccines and adjuvants: the HPV paradigm.Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.Confronting the barriers to develop novel vaccines against brucellosis.Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.Virus-based nanoparticles as platform technologies for modern vaccines.An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.Adjuvant activity of saponins from Kazakhstani plants on the immune responses to subunit influenza vaccine.Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity.Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody.Administration of naloxone in combination with recombinant Plasmodium vivax AMA-1 in BALB/c mice induces mixed Th1/Th2 immune responses.Vaccine adjuvants: smart components to boost the immune system.Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Gamma-irradiated rotavirus: A possible whole virus inactivated vaccine.Stimuli-Responsive Polymers as Adjuvants and Carriers for Antigen Delivery
P2860
Q21284959-A6647D9F-CEB8-4F0F-8697-7AE73B9C7F48Q27010434-C5B6E51E-40BF-415D-B406-02EEF1FF9CA2Q28474115-AB52790E-6C76-4B9A-A9B8-6D4C9C66D977Q30377224-488724E0-23C5-4653-B615-A5D6541B28A8Q30388063-814D8635-FD2E-4F89-BD4F-0A42A549DBE8Q30401036-EC9E6C75-79BE-4A37-858B-2914142A256DQ33710195-F4C95755-07BC-45AA-ACEA-083A9F64DA98Q33724967-FAB8ABCE-90B3-4EE0-8D99-4AD27E394BFCQ33729612-F5134835-495A-46F1-A061-E8A2A2D8C030Q34009465-06AD93FF-A78D-4C61-BDBC-7CD645929F52Q35127314-A2E3C628-BA4B-4CD9-9A25-DC78080C8827Q35664854-CADFCAE1-BA12-494F-85E0-55B444E126A8Q35826651-1E10595D-5BB2-4A0B-A656-40766853FCB4Q35848642-E18071E6-39B1-4764-89F0-89B6E6D0FCBFQ35981265-2B5B6112-7110-4325-AC5A-A075385CAED4Q36143523-D668F065-9C25-410E-BA35-8365F78D8A71Q36607397-D6E0C3AE-D250-4678-91C6-0BEF642E3CB7Q37077649-4B7072EE-B36C-437C-BBFF-7A51F310AF7DQ37188632-6401AAE9-73E1-492E-AADE-E64CC8C8F107Q37242289-4584D35D-9CC5-460B-A59F-71642B6C529EQ37289261-22662D58-9E6C-4B71-ACFE-2722BB5861EAQ37426321-85AD2859-FBF7-4D77-BB05-59BBE63B0F00Q37442424-1505EB96-FBD6-41C2-94C4-9EDE568193F7Q37608311-B7EF1C67-96D6-4256-8A7E-AA3F0DA3F93CQ37792984-E5A9DB4B-379D-45E0-B602-412854B351DCQ37932521-FA385871-6E5F-4AB4-82D1-4A545CE128A0Q37969751-B3BEABDB-3F08-4607-9F71-3F67079ABD68Q38702017-840C524F-4F93-4FC4-B9D1-2385456693B5Q39174792-744CB36C-400D-4B4B-9D44-FF68C890B635Q41932371-2A066AAB-3450-4134-B962-3BFA362F6BFFQ42134087-49469355-1247-41DD-A5AB-87DB2503ADEDQ42261896-4F225AB2-E58C-4668-9A99-F722B3808E21Q44267619-2B44C2DC-F7F1-4D2B-A102-04B8E2EE92FCQ47923410-71133ADA-869F-4A05-AA27-1C7D61EA15A8Q50063256-050F18E6-4CDB-4EB3-B9FA-6E96C4835DC9Q54448728-906FE924-B592-47DA-AE5A-B6C5ECDD8B2DQ55085319-3834FC67-2F29-49D1-ACA7-58D89B83973BQ55405177-F05F8939-0021-41AC-BD74-9081B01CCD7FQ57340495-723DAC46-127A-4A13-813C-173F5A1FF122
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Improving vaccine performance with adjuvants.
@ast
Improving vaccine performance with adjuvants.
@en
type
label
Improving vaccine performance with adjuvants.
@ast
Improving vaccine performance with adjuvants.
@en
prefLabel
Improving vaccine performance with adjuvants.
@ast
Improving vaccine performance with adjuvants.
@en
P2860
P356
P1476
Improving vaccine performance with adjuvants.
@en
P2093
P2860
P304
P356
10.1086/313883
P407
P478
30 Suppl 3
P577
2000-06-01T00:00:00Z